Cancer Drug Shows Promise in Slowing Parkinson's Disease
Scientists have discovered that an existing cancer immunotherapy drug, nivolumab–relatlimab, shows promise in slowing Parkinson’s disease progression by blocking the spread of toxic protein clumps in the brain, through disrupting a partnership between two proteins, LAG-3 and Aplp1, involved in the disease mechanism. This repurposing could lead to new treatments that slow or halt disease progression.
